Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - REVA Medical, Inc. | rva-ex991_8.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report: January 8, 2018 (Date of earliest event reported) |
|
REVA MEDICAL, INC. |
|
(Exact name of registrant as specified in its charter)
|
|
Delaware |
000-54192 |
33-0810505 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
5751 Copley Drive, San Diego, CA |
92111 |
|
(Address of principal executive offices) |
(Zip Code) |
|
(858) 966-3000 |
|
(Registrant’s telephone number, including area code) |
|
|
|
|
|
(Former Name or Former Address, if changed since last report) |
|
|
|
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
|
|
|
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). |
|
|
|
Emerging growth company ☐ |
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |
Item 7.01 Regulation FD Disclosure
The information attached as Exhibit 99.1 to this report relating to REVA Medical, Inc. (“REVA” or the “Company”) will be presented during investor and analyst meetings during the JP Morgan 36th Annual Healthcare Conference from January 8, 2018 through January 11, 2018 in San Francisco, CA and from time to time by the Company at various other investor and analyst meetings.
Limitation of Incorporation by Reference
In accordance with General Instruction B.2 of Form 8-K, this information including the Exhibit is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
|
Exhibit Number |
|
Description |
|
99.1 |
|
Presentation entitled “REVA Medical Corporate Presentation January 2018” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
REVA Medical, Inc. |
|
|
|
|
|
|
|
Date: January 8, 2018 |
/s/ Brandi L. Roberts |
|
|
Brandi L. Roberts |
|
|
Chief Financial Officer and Corporate Secretary |